Trial Profile
A Prospective, Randomized, Open-Label, 13 to 14-week Study of the Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Subjects With Left Ventricular Hypertrophy (LVH)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nebivolol/valsartan (Primary) ; Valsartan (Primary)
- Indications Hypertension; Left ventricular hypertrophy
- Focus Therapeutic Use
- Acronyms BVreduce
- 10 Apr 2018 Status changed from recruiting to completed.
- 13 Jun 2017 New trial record